Overview Dividends

(ANIP) ANI Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00182C1036

Injectables, Softgels, Cortrophin, Iluvien, Yutiq

Pharmaceuticals
Market Cap in USD: 1,761m

IPO / Inception: 2000-05-05
Return 12m vs S&P 500: 23.3%

EPS (Earnings per Share)

EPS CAGR: 5.71%
EPS Trend: 6.5%

Last SUE: -3.37
Qual. Beats: 0

Revenue

Rev. CAGR: 42.15%
Rev. Trend: 98.4%

Last SUE: 2.54
Qual. Beats: 4

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	33.9%
Value at Risk 5%th	51.7%
Relative Tail Risk	-7.36%

Reward TTM
Sharpe Ratio	1.08
Alpha	30.96
CAGR/Max DD	0.97

Character TTM
Hurst Exponent	0.709
Beta	0.587
Beta Downside	0.310

Drawdowns 3y
Max DD	25.54%
Mean DD	10.06%
Median DD	10.13%

Description: ANIP ANI Pharmaceuticals November 13, 2025

ANI Pharmaceuticals (NASDAQ: ANIP) is a U.S.-based biopharmaceutical firm that designs, manufactures, and markets both branded and generic injectable, oral, and topical medicines, including specialty products such as Cortrophin gel, ILUVIEN, and YUTIQ. Its distribution network spans wholesalers, retail chains, specialty pharmacies, GPOs, hospitals, and physicians, allowing it to reach a broad domestic and international patient base.

Key operating metrics (as of the latest 10-K) show FY 2023 revenue of $215 million, a year-over-year increase of roughly 8 % driven by higher generic injectable volumes, and an adjusted EBITDA margin near 12 %. The company’s pipeline includes several FDA-pending generics in high-demand therapeutic areas (e.g., oncology and endocrinology), which could lift future top-line growth if approvals materialize. Sector-wide, the U.S. generic injectable market is expected to expand at a 4-5 % CAGR through 2028, supported by an aging population and ongoing cost-containment pressure on payers.

For a deeper dive into ANIP’s valuation metrics and peer comparison, you may find ValueRay’s analyst tools useful.

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (38.1m TTM) > 0 and > 6% of Revenue (6% = 49.6m TTM)

FCFTA 0.10 (>2.0%) and ΔFCFTA 3.84pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 51.74% (prev 59.66%; Δ -7.91pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 170.7m > Net Income 38.1m (YES >=105%, WARN >=100%)

Net Debt (60.0m) to EBITDA (163.6m) ratio: 0.37 <= 3.0 (WARN <= 3.5)

Current Ratio 2.58 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (21.1m) change vs 12m ago 8.70% (target <= -2.0% for YES)

Gross Margin 58.40% (prev 59.79%; Δ -1.39pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 61.35% (prev 43.15%; Δ 18.21pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 2.67 (EBITDA TTM 163.6m / Interest Expense TTM 27.1m) >= 6 (WARN >= 3)

Altman Z'' 2.18

(A) 0.30 = (Total Current Assets 698.4m - Total Current Liabilities 270.6m) / Total Assets 1.41b

(B) -0.04 = Retained Earnings (Balance) -50.6m / Total Assets 1.41b

(D) -0.05 = Book Value of Equity -47.8m / Total Liabilities 902.3m

Total Rating: 2.18 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 68.72

1. Piotroski 5.0pt

2. FCF Yield 7.43%

3. FCF Margin 16.37%

4. Debt/Equity 0.64

5. Debt/Ebitda 0.37

6. ROIC - WACC (= -1.74)%

7. RoE 8.28%

8. Rev. Trend 98.39%

9. EPS Trend 6.54%

What is the price of ANIP shares?

As of January 08, 2026, the stock is trading at USD 79.47 with a total of 317,410 shares traded.
Over the past week, the price has changed by +0.67%, over one month by -2.30%, over three months by -13.32% and over the past year by +46.14%.

Is ANIP a buy, sell or hold?

ANI Pharmaceuticals has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ANIP.

Strong Buy: 3
Buy: 2
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ANIP price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	109.3	37.5%
Analysts Target Price	109.3	37.5%
ValueRay Target Price	93.2	17.3%

ANIP Fundamental Data Overview January 04, 2026

Market Cap USD = 1.76b (1.76b USD * 1.0 USD.USD)
P/E Trailing = 49.0188
P/E Forward = 9.2678
P/S = 2.1302
P/B = 3.5049
P/EG = 1.06
Beta = 0.484
Revenue TTM = 826.9m USD
EBIT TTM = 72.2m USD
EBITDA TTM = 163.6m USD
Long Term Debt = 605.1m USD (from longTermDebt, last quarter)
Short Term Debt = 15.2m USD (from shortTermDebt, last quarter)
Debt = 322.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 60.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.82b USD (1.76b + Debt 322.6m - CCE 262.6m)
Interest Coverage Ratio = 2.67 (Ebit TTM 72.2m / Interest Expense TTM 27.1m)
FCF Yield = 7.43% (FCF TTM 135.3m / Enterprise Value 1.82b)
FCF Margin = 16.37% (FCF TTM 135.3m / Revenue TTM 826.9m)
Net Margin = 4.61% (Net Income TTM 38.1m / Revenue TTM 826.9m)
Gross Margin = 58.40% ((Revenue TTM 826.9m - Cost of Revenue TTM 344.0m) / Revenue TTM)
Gross Margin QoQ = 49.07% (prev 64.70%)
Tobins Q-Ratio = 1.29 (Enterprise Value 1.82b / Total Assets 1.41b)
Interest Expense / Debt = 1.47% (Interest Expense 4.73m / Debt 322.6m)
Taxrate = 21.25% (7.18m / 33.8m)
NOPAT = 56.9m (EBIT 72.2m * (1 - 21.25%))
Current Ratio = 2.58 (Total Current Assets 698.4m / Total Current Liabilities 270.6m)
Debt / Equity = 0.64 (Debt 322.6m / totalStockholderEquity, last quarter 505.8m)
Debt / EBITDA = 0.37 (Net Debt 60.0m / EBITDA 163.6m)
Debt / FCF = 0.44 (Net Debt 60.0m / FCF TTM 135.3m)
Total Stockholder Equity = 459.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.70% (Net Income 38.1m / Total Assets 1.41b)
RoE = 8.28% (Net Income TTM 38.1m / Total Stockholder Equity 459.9m)
RoCE = 6.78% (EBIT 72.2m / Capital Employed (Equity 459.9m + L.T.Debt 605.1m))
RoIC = 5.35% (NOPAT 56.9m / Invested Capital 1.06b)
WACC = 7.09% (E(1.76b)/V(2.08b) * Re(8.18%) + D(322.6m)/V(2.08b) * Rd(1.47%) * (1-Tc(0.21)))
Discount Rate = 8.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.76%
[DCF Debug] Terminal Value 69.86% ; FCFE base≈110.9m ; Y1≈72.8m ; Y5≈33.3m
Fair Price DCF = 28.48 (DCF Value 639.7m / Shares Outstanding 22.5m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 6.54 | EPS CAGR: 5.71% | SUE: -3.37 | # QB: 0
Revenue Correlation: 98.39 | Revenue CAGR: 42.15% | SUE: 2.54 | # QB: 4
EPS next Quarter (2026-03-31): EPS=1.62 | Chg30d=-0.063 | Revisions Net=+4 | Analysts=5
EPS next Year (2026-12-31): EPS=8.53 | Chg30d=+0.156 | Revisions Net=+6 | Growth EPS=+13.3% | Growth Revenue=+9.8%

Additional Sources for ANIP Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle